Clinical Research Directory
Browse clinical research sites, groups, and studies.
JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation
Sponsor: Allist Pharmaceuticals, Inc.
Summary
This Phase 3 study will evaluate the efficacy of JAB-21822+JAB-3312 versus tislelizumab (PD-1 Ab) combined with pemetrexed+carboplatin as the first line treatment in subjects with KRAS G12C mutated locally advanced or metastatic non-small cell lung cancer (NSCLC).
Official title: An Open-label, Randomized, Positive Control, Multicenter Phase III Clinical Study. Evaluating JAB-21822 Combined With JAB-3312 Compared Tislelizumab Combined With Pemetrexed + Carboplatin in the First Line for Treatment of Advanced Non-squamous Non-small Cell Lung Cancer With KRAS p.G12C Mutation
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
392
Start Date
2024-08-07
Completion Date
2027-02-28
Last Updated
2025-04-04
Healthy Volunteers
No
Conditions
Interventions
JAB-21822
JAB-21822 administered orally as a tablet
Tislelizumab
Tislelizumab administered as an intravenous (IV) infusion
JAB-3312
JAB-3312 administered orally as a tablet or capsule
Pemetrexed
Pemetrexed administered as an intravenous (IV) infusion
Carboplatin
Carboplatin administered as an intravenous (IV) infusion
Locations (37)
Anhui Province cancer hospital
Hefei, Anhui, China
Pecking Union Medical College Hospital
Beijing, Beijing Municipality, China
Cancer Hospital Chinese Academy Of Medical Sciences
Beijing, Beijing Municipality, China
Beijing Tiantan Hospital, Captal Medical University
Beijing, Beijing Municipality, China
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Peking University Third Hospital
Beijing, Beijing Municipality, China
Beijing Chest Hospital ,Capital Medical University
Beijing, Beijing Municipality, China
Fujian cancer Hospital
Fuzhou, Fujian, China
The first Affiliated Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China
Cancer Hospital Chinese Academy Of medical Sciences Shenzhen Center
Shenzhen, Guangdong, China
Guangxi Medical University Cancer hospital & Guangxi Cancer Institute
Nanning, Guangxi, China
Cangzhou hospital of integrated TCM-WM Hebei
Cangzhou, Hebei, China
Harbin Medical University Cancer Hospital-Mammary gland of internal
Haerbin, Heilongjiang, China
Henan Cancer Hospital
Zhengzhou, Henan, China
The First Affiliated Hosipital Of Zhengzhou University
Zhengzhou, Henan, China
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, Hubei, China
Tongji Hospital Tongji Medical College of Hust
Wuhan, Hubei, China
Hubei cancer hospital
Wuhan, Hubei, China
Hunan Cancer Hospital
Changsha, Hunan, China
Jiangsu province hospital
Nanjing, Jiangsu, China
Wuxi People's Hospital
Wuxi, Jiangsu, China
Jilin cancer hospital
Jilin, Jilin, China
The First Hospital Of China Medical University
Shenyang, Liaoning, China
Liaoning Cancer Hospital & Institute
Shenyang, Liaoning, China
Shandong Cancer Hospital
Jinan, Shandong, China
LinYi Cancer Hospital
Linyi, Shandong, China
The affiliated hospital of Qingdao university
Qingdao, Shandong, China
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China
Shanxi province cancer hospital
Taiyuan, Shanxi, China
The First Affiliated Hospital of Xi'An Jiaotong University
Xi’an, Shanxi, China
Sichuan province cancer hospital
Chengdu, Sichuan, China
West China Hospital Sichuan University
Chengdu, Sichuan, China
Tianjin Medical University Cancer Institute Hospital
Tianjin, Tianjin Municipality, China
The First affiliated hospital Zhejiang university school of medicine
Hangzhou, Zhejiang, China
The Second Affiliated Hospital Zhejiang School of Medicine
Hangzhou, Zhejiang, China
Taizhou Hospital Zhejiang Province
Taizhou, Zhejiang, China